2018 Investor Presentation

Lantheus Reports First Quarter 2023 Financial Results
Worldwide revenue of $300.8 million for the first quarter 2023, representing an increase of 44.0% from the prior year period GAAP net loss of $2.8 million for the first quarter 2023, compared to GAAP net income of $43.0 million in the prior year period GAAP fully diluted net loss per share of $.04
May 4, 2023
Lantheus Announces Two Key Executive Promotions
Paul Blanchfield promoted to President; Dan Niedzwiecki promoted to Chief Administrative Officer BEDFORD, Mass. , March 17, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and
March 17, 2023
Lantheus Reports Fourth Quarter and Full Year 2022 Financial Results
Worldwide revenue of $263.2 million and $935.1 million for the fourth quarter and full year 2022, representing increases of 103.1% and 119.9% over the prior year periods, respectively GAAP net loss of $119.2 million and GAAP net income of $28.1 million for the fourth quarter and full year 2022,
February 23, 2023
Lantheus to Present at the J.P. Morgan 2023 Healthcare Conference
NORTH BILLERICA, Mass. , Jan. 04, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc.  (“the Company”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow
January 4, 2023